ALVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alvotech SA (ALVO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown a recent price increase, the technical indicators are neutral to bearish, and the financial performance shows declining net income and EPS. Additionally, there are no strong trading signals or significant positive catalysts to justify immediate investment.
The MACD histogram is negative (-0.0264) and contracting, indicating weak momentum. RSI is neutral at 51.699, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 4.235), suggesting limited short-term upside.
Alvotech has five biosimilars approved and marketed globally, focusing on autoimmune disorders and eye diseases. The company has also formed strategic commercial partnerships to enhance market reach.
The stock has a 40% chance of declining in the next day (-2.19%) and next month (-1.41%). Analyst coverage initiated with an 'Underweight' rating and a $5 price target, indicating limited growth expectations.
In Q3 2025, revenue increased by 10.56% YoY to $113.86M, but net income dropped by 53.90% YoY to -$5.25M. EPS also declined by 50.00% YoY to -$0.02. Gross margin improved to 69.26%, up 12.91% YoY.
Barclays initiated coverage with an 'Underweight' rating and a $5 price target, citing a neutral view on the specialty pharmaceuticals industry. While pricing headwinds are easing, the sector remains in a transition phase with limited near-term upside.
